Key Stats for AstraZeneca Stock
- Price change for AstraZeneca stock Today: 3%
- $AZN Share Price as of Mar. 27: $93
- 52-Week High: $97
- $AZN Stock Price Target: $102
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
AstraZeneca (AZN) stock jumped over 3% after the company announced that its experimental lung disease drug, tozorakimab, hit its targets in two late-stage clinical trials.
The drug reduced flare-ups of chronic obstructive pulmonary disease, or COPD, in both former smokers and the broader patient population compared to placebo.
That’s a big deal.
Two rival drugs — one from Roche and one from Sanofi — had previously failed with the same mechanism, so investors weren’t expecting much.
Jefferies analysts noted the results mark “a notable shift in sentiment” given how little confidence the market had in the IL-33 drug class after those earlier failures.
What makes tozorakimab different?
According to AstraZeneca’s own R&D head, it works by blocking both forms of the IL-33 protein — not just one — which helps reduce inflammation and break the cycle of mucus buildup that drives COPD symptoms.
The trial results also showed benefit for patients with low eosinophil counts, a group that makes up about 35% of COPD patients and has historically had few treatment options.
See analysts’ growth forecasts and price targets for AstraZeneca stock (It’s free) >>>
What the Market Is Telling Us About AstraZeneca Stock
This is a meaningful win for AstraZeneca stock.
- Before Friday’s results, analyst consensus had penciled in peak annual sales of around $1 billion for tozorakimab.
- AstraZeneca itself is targeting $3 billion to $5 billion at peak — and those numbers now look a lot more credible.
- COPD affects nearly 400 million people globally and is the world’s third leading cause of death.
It’s a massive market, and tozorakimab appears to be the first IL-33 biologic to successfully clear two Phase III trials in this disease.
The ripple effect was real, too.
Shares of Roche and Sanofi each rose about 1% on the news, suggesting the market sees this as a positive signal for the broader drug class.
AstraZeneca stock is already on a strong long-term trajectory, with the company targeting $80 billion in annual sales by 2030 and planning to launch more than 20 new drugs over the next five years.
A drug with multi-billion-dollar peak sales potential adds meaningful weight to that ambition.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does AstraZeneca Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
